Dose-dependent decrease in Top1 levels in A375 xenografts. by Thomas D. Pfister (107712)

Tumor volume decreases with increasing <i>Salmonella</i> dosage. by Robert A. Kazmierczak (3140379)

Table_1_A Strong Decrease in TIMP3 Expression Mediated by the Presence of miR-17 and 20a Enables Extracellular Matrix Remodeling in the NSCLC Lesion Surroundings.DOCX by Karolina H. Czarnecka (8121305)

“…</p><p>Results: The MMP2 has been expressed on a similar level in NLNT, as in cancer. While, TIMP3 expression was decreased both in cancer tissue and NLNT, with significantly lower expression in cancer. …”

Thaliporphine significantly decreased cardiomyocytes apoptosis. by A. S. Lee (318348)

Diclofenac decreases angiogenesis. by Nina Mayorek (241888)

BMR decreases with age. by Henrik H. Berntsen (11767710)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Decreased lysosomal function. by Shuyan Lu (488931)

UCHL1 depletion decreases Wnt signaling activity. by Patricia C. Sanchez-Diaz (403746)

Observed decreases in capacity. by Robert L. Burdett (17364685)

Mitigation (decreasing) scenario. by Fabio Correddu (12501799)

The decrease in 2774 ovarian cancer cell migration and invasion as a result of Tβ₁₀ overexpression. by Young-Chae Kim (163381)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

Recombinant SFRP3 decreases migration and invasion of melanoma cells. by Elin J. Ekström (225100)

Novel chromobox 2 inhibitory peptide decreases tumor progression by Lindsay W. Brubaker (15099942)

Sample demographic information (N = 21). by Ethan Simpson (12355558)

Subjects:

S1 Data - by Ethan Simpson (12355558)

Subjects:

Number of participants outside cut-off score. by Ethan Simpson (12355558)

Subjects:

BrdU incorporation is elevated in clrn1-/- zebrafish at 4 mpf and decreases with age. by Hannah J. T. Nonarath (20861735)

“…(*p<0.05; **p<0.01; One-way ANOVA). Scale bar=10 µm. Data points are averages of 3 sections per retina. n=10 retina per genotype for each time-point.…”

Mean per-participant costs by condition at baseline based on a 3-month recall period (€, indexed for 2022). Data are presented as mean (standard deviation). The cost prices utilize... by Ruben M.W.A. Drost (21647598)

Subjects: